Skip to content

Concert Pharmaceuticals, Inc.

CIK 0001367920

← back to feed
Revenue (TTM)
$572K
+465,300.0% YoY Q3 Nov 2022
Net Income (TTM)
−$116.86M
−257.5% YoY Q3 Nov 2022
EPS Diluted (TTM)
−$2.98
+2.9% YoY Q3 Nov 2022
Gross Margin
—
Q3 Nov 2022
Operating Margin
-20,649.0%
Q3 Nov 2022
Net Margin
-20,429.7%
Q3 Nov 2022
Free Cash Flow (TTM)
−$72.82M
Q3 Nov 2022
Cash
$95.19M
Q3 Nov 2022
Total Debt
$29.19M
Q3 Nov 2022
Shares Outstanding
47.94M sh
Q3 Nov 2022

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings